Epigenetic Drugs: Team Players in Combo Therapies
Scientists May Be Better Able to Destroy Tumors and Possibly Reverse CNS Decline
Toward a Universal Flu Vaccine
New Candidate Fights Back against the Flu’s Efforts to Undermine the Human Immune System
Bioelectricity, New Peer Reviewed Journal Announced
An Outstanding and Influential Foundation for a Dynamic, Emerging Field
The Challenge of Immunotherapy: Staying on Target
Immunotherapies Can Produce Side Effects That Mimic Autoimmune Diseases
For full access to this article login to GEN Select now.
U.K. Biopharma Bouncing Back
Advantages Include 30 Leading Universities and Womb-to-Tomb Electronic Health Records
- 2012 is looking like a better year for the U.K.’s biopharm sector. Recently, a pharma heavyweight entered the ring and is banking on the region’s biomanufacturing abilities. GlaxoSmithKline recently announced an investment of over £500 million in U.K. biopharmaceutical manufacturing. Since the money is going to be spent ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.